Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.85
+$0.105 · +6.02%
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
Latest quote
$1.85
+$0.105 · +6.02%
After-hours
$2.2203
+$0.3703 · +20.02%
Oct 8, 5:21 PM ET
Regular session · ET · Market data may be delayed.
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
Day range
Current $1.85
52-week range
Current $1.85
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
58
Mixed
Risk
51
Elevated Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
Day range
Current $1.85
52-week range
Current $1.85
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 111.64K USD | — | — | 18.02K USD |
| Gross profit | — | −111.64K USD | — | — | −18.02K USD |
| Research and development | 574.94K USD | 175K USD | 2.42M USD | 9.16M USD | 856.82K USD |
| Selling, general, and administrative | 1.83M USD | 3.63M USD | 2.23M USD | 3.28M USD | 2.05M USD |
| Operating expenses | 3.26M USD | 3.81M USD | 6.05M USD | 12.43M USD | 3.66M USD |
| Interest income | 41.87K USD | 116.05K USD | 253.54K USD | 140.25K USD | — |
| Interest expense | — | — | — | — | 5.63K USD |
| Depreciation and amortization | 112.12K USD | 117.27K USD | 139.69K USD | 74.87K USD | 17.64K USD |
| Operating income | −3.26M USD | −3.92M USD | −6.05M USD | −12.43M USD | −3.68M USD |
| Net income | −2.66M USD | −3.15M USD | −2.16M USD | −10.45M USD | −1.66M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jan 31, 2014 | $0.0001Quarterly | Feb 4, 2014 | Feb 17, 2014 |
Dividend | Oct 15, 2013 | $0.0001Quarterly | Oct 17, 2013 | Nov 1, 2013 |
Dividend | Jul 11, 2013 | $0.0001Quarterly | Jul 15, 2013 | Jul 30, 2013 |
Dividend | Apr 16, 2013 | $0.0001Quarterly | Apr 18, 2013 | May 2, 2013 |
Dividend | Dec 24, 2012 | $0.0001Quarterly | Dec 27, 2012 | Dec 31, 2012 |
Dividend | Oct 12, 2012 | $0.0001Quarterly | — | Oct 30, 2012 |
Ex-dividend Jan 31, 2014
$0.0001
Quarterly
Record Feb 4, 2014 · Payment Feb 17, 2014
Ex-dividend Oct 15, 2013
$0.0001
Quarterly
Record Oct 17, 2013 · Payment Nov 1, 2013
Ex-dividend Jul 11, 2013
$0.0001
Quarterly
Record Jul 15, 2013 · Payment Jul 30, 2013
Ex-dividend Apr 16, 2013
$0.0001
Quarterly
Record Apr 18, 2013 · Payment May 2, 2013
Ex-dividend Dec 24, 2012
$0.0001
Quarterly
Record Dec 27, 2012 · Payment Dec 31, 2012
Ex-dividend Oct 12, 2012
$0.0001
Quarterly
Payment Oct 30, 2012
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
